Lyell Immunopharma (NASDAQ:LYEL – Get Free Report) and Zenas BioPharma (NASDAQ:ZBIO – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.
Profitability
This table compares Lyell Immunopharma and Zenas BioPharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lyell Immunopharma | -920,285.25% | -91.62% | -70.50% |
| Zenas BioPharma | N/A | -122.45% | -58.04% |
Insider and Institutional Ownership
66.0% of Lyell Immunopharma shares are held by institutional investors. 6.2% of Lyell Immunopharma shares are held by insiders. Comparatively, 22.0% of Zenas BioPharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lyell Immunopharma | 1 | 1 | 6 | 1 | 2.78 |
| Zenas BioPharma | 1 | 2 | 6 | 0 | 2.56 |
Lyell Immunopharma currently has a consensus target price of $40.86, indicating a potential upside of 184.32%. Zenas BioPharma has a consensus target price of $45.71, indicating a potential upside of 39.03%. Given Lyell Immunopharma’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Lyell Immunopharma is more favorable than Zenas BioPharma.
Risk & Volatility
Lyell Immunopharma has a beta of -0.04, suggesting that its share price is 104% less volatile than the S&P 500. Comparatively, Zenas BioPharma has a beta of -1.04, suggesting that its share price is 204% less volatile than the S&P 500.
Valuation and Earnings
This table compares Lyell Immunopharma and Zenas BioPharma”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lyell Immunopharma | $40,000.00 | 8,801.62 | -$274.45 million | ($12.83) | -1.12 |
| Zenas BioPharma | $1.00 million | 2,143.02 | -$377.74 million | ($8.99) | -3.66 |
Lyell Immunopharma has higher earnings, but lower revenue than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.
Summary
Lyell Immunopharma beats Zenas BioPharma on 9 of the 14 factors compared between the two stocks.
About Lyell Immunopharma
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
About Zenas BioPharma
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.
Receive News & Ratings for Lyell Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyell Immunopharma and related companies with MarketBeat.com's FREE daily email newsletter.
